Bupropion and Counseling With or Without Contingency Management to Enhance Smoking Cessation in Treating Cancer Survivors Who Continue to Smoke
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00079469|
Recruitment Status : Completed
First Posted : March 10, 2004
Last Update Posted : March 8, 2012
RATIONALE: Contingency management is a behavioral treatment approach that provides immediate rewards for positive change in behavior such as quitting smoking. In this protocol, contingency management will be in the form of a cash reward. A smoking cessation (stop-smoking) program that combines contingency management with bupropion and counseling may be effective in helping cancer survivors stop smoking.
PURPOSE: Randomized clinical trial to compare the effectiveness of bupropion and counseling with or without contingency management in helping cancer survivors stop smoking.
|Condition or disease||Intervention/treatment||Phase|
|Cancer Survivor Unspecified Adult Solid Tumor, Protocol Specific||Behavioral: smoking cessation intervention Drug: bupropion hydrochloride||Not Applicable|
- Compare the feasibility of a multi-component smoking cessation intervention comprising bupropion and counseling with or without contingency management (cash reward) for cancer survivors who continue to smoke.
- Compare 7-day point-prevalence abstinence rates in patients treated with these smoking cessation interventions.
- Determine the characteristics of these patients that predict success at quitting smoking.
OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 smoking cessation intervention arms.
- Arm I: Patients receive oral bupropion twice daily on weeks 1-12 and brief practical counseling (i.e., problem-solving strategies, stimulus control, stress management, and social support) on weeks 1-6.
- Arm II: Patients receive treatment as in arm I and contingency management (i.e., monetary reinforcement for not smoking) on weeks 1-6.
In both arms, treatment continues in the absence of unacceptable toxicity.
Patients are followed at 12 and 24 weeks after the completion of the smoking cessation interventions.
PROJECTED ACCRUAL: A total of 100 patients (50 per intervention arm) will be accrued for this study within 8 months.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Contingency Management to Enhance Smoking Cessation for Cancer Survivors: A Proof of Concept Trial|
|Study Start Date :||February 2004|
|Actual Study Completion Date :||August 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00079469
|United States, Maryland|
|Tobacco Control Research Branch|
|Rockville, Maryland, United States, 20852|
|Principal Investigator:||Glen D. Morgan, PhD||NCI - Division of Cancer Control and Population Science|
|OverallOfficial:||Sandra J. Schaefer, RN, BSN, OCN||National Cancer Institute (NCI)|